Bio Path traded at $0.07 this Friday February 20th, decreasing $0.001 or 1.97 percent since the previous trading session. Looking back, over the last four weeks, Bio Path lost 25.24 percent. Over the last 12 months, its price fell by 67.56 percent. Looking ahead, we forecast Bio Path to be priced at 0.06 by the end of this quarter and at 0.05 in one year, according to Trading Economics global macro models projections and analysts expectations.
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the Deoxyribonucleic acid (DNA) from destruction by the body’s enzymes. Its lead drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2 (Grb2), the efficacy portion of a Phase II clinical trial for untreated acute myeloid leukemia (AML) patients in combination with low-dose cytarabine (LDAC). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival for all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein and is enabling studies as a potential treatment for pancreatic cancer, non-small cell lung cancer (NSCLC) and AML.